The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Its a major breakthrough for women’s ovarian cancer care in Europe
This marks a meaningful step in the company's continued expansion in the region
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Subscribe To Our Newsletter & Stay Updated
